The Need For Interim Assessment Of Neoadjuvant Chemotherapy Response For Muscle Invasive Bladder Cancerdcan We Help Prevent Definitive Treatment Delay In Nonresponders?

No AccessJournal of UrologyJU Forum1 Feb 2021The Need for Interim Assessment of Neoadjuvant Chemotherapy Response for Muscle Invasive Bladder Cancer—Can We Help Prevent Definitive Treatment Delay in Nonresponders? Subodh K. Regmi, Arveen Kalapara, and Badrinath R. Konety Subodh K. RegmiSubodh K. Regmi *Correspondence: Department of Urology, University of Minnesota, 420 Delaware St. SE, Minneapolis, Minnesota 55455 telephone: 612-625-8364; E-mail Address: [email protected] Department of Urology, University of Minnesota, Minneapolis, Minnesota More articles by this author , Arveen KalaparaArveen Kalapara Department of Urology, University of Minnesota, Minneapolis, Minnesota More articles by this author , and Badrinath R. KonetyBadrinath R. Konety Department of Urology, University of Minnesota, Minneapolis, Minnesota More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001381AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail REFERENCES 1. : Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: a pathologic stage-matched analysis. Eur Urol 2017; 72: 660. Google Scholar 2. : Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Cancer 2019; 125: 3155. Google Scholar 3. : Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data. BJU Int 2019; 123: 818. Google Scholar 4. : FDG-PET/CT for assessing the response to neoadjuvant chemotherapy in bladder cancer patients. Clin Genitourin Cancer 2018; 16: 360. Google Scholar 5. : Prognostic significance of cystoscopy findings following neoadjuvant chemotherapy for muscle-invasive bladder cancer. Can J Urol 2015; 22: 7690. Google Scholar 6. : Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma. Urol Oncol 2020; 38: 684.e9. Google Scholar © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 205Issue 2February 2021Page: 327-329 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.Keywordscystoscopyneoadjuvant therapytime-to-treatmentcystectomyresponse evaluation criteria in solid tumorsACKNOWLEDGMENTSPeter T. F. Hannah, MD helped with data collection during this research.MetricsAuthor Information Subodh K. Regmi Department of Urology, University of Minnesota, Minneapolis, Minnesota *Correspondence: Department of Urology, University of Minnesota, 420 Delaware St. SE, Minneapolis, Minnesota 55455 telephone: 612-625-8364; E-mail Address: [email protected] More articles by this author Arveen Kalapara Department of Urology, University of Minnesota, Minneapolis, Minnesota More articles by this author Badrinath R. Konety Department of Urology, University of Minnesota, Minneapolis, Minnesota More articles by this author Expand All Advertisement PDF DownloadLoading ...